On Thursday, Shares of Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP), gained 4.63% to $8.59.
Synergy Pharmaceuticals declared positive top-line results from the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses (3.0 mg and 6.0 mg), taken as a tablet once-a-day, in 1337 adult patients with chronic idiopathic constipation (CIC).
Preliminary analysis of the data indicates that both plecanatide 3.0 mg and 6.0 mg doses met the study’s primary endpoint and demonstrated statistical significance in the proportion of patients in the intention-to-treat population who were durable overall responders contrast to placebo during the 12-week treatment period (20.1% in 3.0 mg and 20.0% in 6.0 mg dose groups contrast to 12.8% in placebo; p=0.004 for both doses). The durable overall responder endpoint is the current FDA endpoint required for US approval in CIC. Importantly, plecanatide was safe and well tolerated at both doses; the most common adverse event was diarrhea, which occurred in 3.2% of patients in 3.0 mg and 4.5% of patients in 6.0 mg dose groups contrast to 1.3% of placebo-treated patients.
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders; and for the treatment of constipation-predominant irritable bowel syndrome GI disorders.
Shares of Mylan N.V. (NASDAQ:MYL), declined -1.55% to $56.35, during its last trading session.
Mylan declared that it will hold its extraordinary general meeting of shareholders in connection with its projected acquisition of Perrigo Company plc (NYSE: PRGO; TASE) at the Okura Hotel Amsterdam on Friday, Aug. 28, 2015 at 1 p.m. Central European Time (CET).
Among other agenda items at the extraordinary general meeting, Mylan shareholders will meet to vote on the approval, under article 2:107a of the Dutch Civil Code, of the acquisition of all or any portion of the ordinary shares of Perrigo outstanding as of the consummation of such acquisition and the issuance of Mylan ordinary shares to Perrigo shareholders as part of the consideration in such acquisition.
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs).
Finally, Terex Corporation (NYSE:TEX), ended its last trade with 1.72% gain, and closed at $22.42.
Terex Corporation declared income from ongoing operations of $85.2 million, or $0.78 per share for the second quarter of 2015, as contrast to income from ongoing operations of $87.8 million, or $0.76 per share for the second quarter of 2014. Net sales were $1,828.5 million in the second quarter of 2015, a decrease of $226.6 million, or 11.0%, when contrast with $2,055.1 million in the second quarter of 2014. Not taking into account the impact of currency, net sales declined about 2.0%. Income from operations was $148.3 million in the second quarter of 2015, a decrease of $12.6 million when contrast to income from operations of $160.9 million in the second quarter of 2014.
“The second quarter was a solid quarter in terms of financial performance,” commented Ron DeFeo, Terex Chairman and Chief Executive Officer. “Our AWP segment operating margin returned to the mid-teens as anticipated, benefiting from raised productivity and seasonally strong sales. We are encouraged by our AWP backlog which is higher than the preceding year level and expect improved performance for this segment in the second half of 2015 as contrast to the second half of 2014. We are seeing pricing pressure in the marketplace, but to date that has been mostly offset by reductions in material input cost.”
Terex Corporation operates as a lifting and material handling solutions company. Its Aerial Work Platforms segment designs, manufactures, services, and markets aerial work platform equipment, telehandlers, and light towers, in addition to related components and replacement parts under Terex and Genie names.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
